XNCR News and Press, Xencor Inc. From 11/08/21

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results f...

Xencor (NASDAQ:XNCR) is scheduled to announce Q3 earnings results on Monday, November 8th, after market close. The consensus EPS Estimate is -$0.76 (-245.5% Y/Y) and the consensus Revenue Estimate is $18.36M (-48.1% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and ...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that updated clinical data from its Phase 1 dose-escalation study of plamotamab, a CD20 ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated clinical data from a Phase 1 study of tidutamab, an SSTR2 x CD3 bispecific antibo...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release third quarter 2021 financial results after the market closes on Mon...

A couple of giant automakers showed strength in Monday's midday action. General Motors (NYSE:GM) advanced on an investment by high-profile hedge fund Engine No. 1, while Ford (NYSE:F) climbed following the release of its monthly sales figures. Elsewhere in the market, Southwest Airlines (NYSE...

-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells -- -- Xencor to receive $100 million upfront payment and $25 million equity investment and is eligible for a mid-teen to low-twenties percent royalty for plamotamab ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference o...

The following slide deck was published by Xencor, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Xencor, Inc. 2021 Q2 - Results - Earnings Call Presentation